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Prevalence of anti-hepatitis E virus (HEV) antibodies is 
highly variable in developed countries, which seems 
partly due to differences in assay sensitivity. Using 
validated sensitive assays, we tested 313 blood donors 
attending a hospital transfusion unit in central Italy in 
January and February 2014 for anti-HEV IgG and IgM 
and HEV RNA. Data on HEV exposure were collected 
from all donors. Overall anti-HEV IgG prevalence was 
49% (153/313). Eating raw dried pig-liver sausage 
was the only independent predictor of HEV infection 
(adjusted prevalence rate ratio = 2.14; 95% confidence 
interval: 1.23–3.74). Three donors were positive for 
either anti-HEV IgM (n = 2; 0.6%) or HEV RNA (n = 2; 
0.6%); they were completely asymptomatic, without 
alanine aminotransferase (ALT) abnormalities. Of the 
two HEV RNA-positive donors (both harbouring geno-
type 3), one was anti-HEV IgG- and IgM-positive, the 
other was anti-HEV IgG- and IgM-negative. The third 
donor was positive for anti-HEV IgG and IgM but HEV 
RNA-negative. HEV infection is therefore hyperendemic 
among blood donors (80% men 18–64 years-old) from 
central Italy and associated with local dietary habits. 
Nearly 1% of donors have acute or recent infection, 
implying potential transmission to blood recipients. 
Neither ALT nor anti-HEV IgM testing seems useful to 
prevent transfusion-transmitted HEV infection.
Introduction
Hepatitis E virus (HEV) is a non-enveloped single-
stranded RNA virus of the genus Hepevirus in the 
Hepeviridae family. This family contains viruses that 
infect mammals, including humans, as well as birds 
and fish. Four major mammalian HEV genotypes (HEV1 
to 4) have been identified [1-3]. HEV, once thought to 
be limited to developing countries, has recently been 
found also in developed countries of Europe, North 
America and Asia-Pacific where human autochthonous 
cases, probably of zoonotic origin, have become preva-
lent [1,2].
HEV1 and HEV2 infect only humans and are endemic 
in developing areas of Asia, Africa and Central and 
South America, where faecal-oral transmission usually 
occurs through contaminated water and causes both 
outbreaks and sporadic cases. Clinical disease mainly 
affects young adults and is severe and associated with 
excess mortality in pregnant women and in patients 
with chronic liver disease [1,2].
HEV3 and HEV4 infect humans and various domestic 
and wild mammals such as pig, wild boar, deer and 
rodents. HEV strains infecting humans and animals 
in the same area are usually phylogenetically closely 
related, supporting zoonotic transmission [1]. HEV3 
is ubiquitous, while HEV4 is mainly prevalent in Asia. 
These genotypes are transmitted by eating contami-
nated raw or undercooked meat and meat products or 
shellfish, and by contact with infected animals, caus-
ing autochthonous sporadic cases [1,2]. Most HEV3 
or HEV4 infections are asymptomatic; clinical disease 
mainly affects middle-aged and elderly men with 
underlying illness, and HEV3 may cause chronic hepa-
titis in immunosuppressed patients [1-3].
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In addition to hepatitis, HEV infection also appears 
to be associated with some extrahepatic manifesta-
tions: neurological disorders such as Guillain–Barré 
syndrome and neuralgic amyotrophy due to peripheral 
nerve involvement, haematological diseases such as 
haemolytic anaemia and severe thrombocytopenia, 
glomerulonephritis and mixed cryoglobulinaemia [4].
Epidemiological studies have reported variable and 
sometimes unexpectedly high prevalence rates of 
IgG anti-HEV antibodies in the general population 
in Europe, ranging from 1.1% to 16.8% in the period 
between 2004 and 2011, although a decline was 
observed for example in south-eastern Germany from 
1996 to 2011 [5-9]. Rates ranging from 0.4% to 52.5% 
have been reported among European blood donors in 
the period between 1993 and 2014, with the highest 
value observed in the Midi-Pyrénées hyperendemic 
area in south-western France [10-18]. In Italy, anti-HEV 
IgG prevalence rates of 1.0–4.3% [19-21] and 0.7–9.1% 
[19,21-23] were found in the general population (in the 
period between 1993 and 2011) and in blood donors 
(in the period between 1993 and 2013), respectively. 
The large variations in anti-HEV prevalence in different 
European countries and even within the same country 
are probably due to several factors such as the perfor-
mance of antibody assays used in the studies but also 
dietary habits and occupational exposure [2,10,11].
HEV can be transmitted by blood transfusion [10,24]. 
Transfusion-transmitted HEV infection has been 
reported in several countries [25-27], but its true fre-
quency is probably underestimated because it is often 
asymptomatic and testing of blood donors is infrequent 
[1,10]. In this study we have assessed the prevalence 
of HEV infection among blood donors in the Abruzzo 
region in central Italy by using highly sensitive and val-
idated assays, and we have examined its association 
with putative risk factors.
Methods
Study population
This study was designed to evaluate the prevalence of 
and the risk factors for HEV infection among voluntary, 
unpaid blood donors attending the blood transfusion 
unit of the San Salvatore Hospital in L’Aquila during 
February and March 2014. L’Aquila is a city of around 
70,000 inhabitants in the Abruzzo region in central 
Italy.
Serum samples were collected from blood donors who 
agreed to participate in the study. Participants were 
administered a questionnaire collecting information on 
demographics and putative risk factors for HEV infec-
tion (professional and recreational activities, contact 
with domestic or wild animals, eating habits and travel 
history).
All blood donors provided written informed con-
sent. The study protocol conformed to the Helsinki 
Declaration and was approved by the Ethics Committee 
of San Salvatore Hospital.
Serological assays
All serum samples were tested for anti-HEV IgG and IgM 
antibodies using commercial enzyme-linked immuno-
sorbent assay (ELISA) kits (Wantai, Biologic Pharmacy 
Enterprise, Beijing, China). Both the IgG and IgM anti-
HEV assays use recombinant antigen expressed from 
the ORF2 region.
Detection and quantitation of hepatitis E virus 
RNA
Plasma samples from anti-HEV IgG-positive or -nega-
tive donors were assembled in minipools of 10 samples 
(20 μL each for a total volume of 200 μL), or fewer if 
a full set of 10 was not available, and total RNA was 
extracted by QIAamp MinElute Virus Spin kit silica col-
umns (Qiagen, Hilden, Germany). Total HEV RNA was 
extracted individually from each anti-HEV IgM-positive 
sample. 
One half of the extracted RNA was reverse tran-
scribed and HEV RNA amplified using the RealStar HEV 
RT-PCR kit, version 1.0 (Altona Diagnostics, Hamburg, 
Germany). This kit includes primers and a probe target-
ing the ORF3 region of the HEV genome. The sensitiv-
ity, reported as 95% limit of detection, was assessed 
to be 50 IU/mL of HEV RNA. Reactive pools were decon-
structed to identify HEV RNA-positive donations by 
individual HEV RNA testing.
An external standard curve, made from a log dilution 
series of a HEV RNA World Health Organization (WHO) 
International Standard (Paul-Ehrlich-Institute, Langen, 
Germany, code 6329/10) from 5 × 104 to 5 × 101 IU/
mL was used for estimating the viral load in positive 
samples.
Sequencing and phylogenetic analysis
HEV RNA was extracted and amplified by nested 
RT-PCR using two sets of primers targeting ORF1 (172 
bp) and ORF2 (348 bp) as described elsewhere [28,29]. 
Purified PCR amplicons were subjected to bidirectional 
automated sequencing. The raw forward and reverse 
ABI files were assembled into a single consensus 
sequence using MEGA 6.06 software. The phylogenetic 
trees were constructed based on the best fit model of 
nucleotide substitution. The reliability of the phyloge-
netic trees were determined by bootstrap re-sampling 
of 1,000 replicates.
Statistical analysis
Prevalence of anti-HEV antibodies (IgG and IgM) and 
HEV RNA was calculated and the exact binomial dis-
tribution was used to calculate 95% confidence inter-
vals (CI). The association between the study variables 
and HEV infection was estimated by chi-squared test. 
Factors independently associated with HEV infection 
were evaluated by a multivariate binomial regression 
model. All variables with a p value < 0.20 in univariate 
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Figure 1
Maximum likelihood phylogenetic tree based on the Tamura-Nei model for ORF1 nucleotide sequences of selected hepatitis 
E virus strains
 Italy 2007 (FR751540) hu
 France 2008 (EU495148) hu
 Italy 2010 (FR751539) hu
 Spain 2008 (EU723516) sw
 Spain 2008 (EU723514) sw
 France 2008 (EU723515) sw
 Germany 2005 (FJ956757) hu
 Italy 2010 (FR751538) hu
 Italy 2010 (FR751537) hu
 Italy 2014 Donor-784 ISS (LN681544)
 Japan 2012 (AB824675) hu
 Italy 2012 (KF896826) sw
 Italy 2012 (KF896825) sw
 France 2006 (JQ953664) sw
 Italy 2014 Donor-771 ISS (LN681543)
 France 2007 (JQ013794) hu
 Italy 1999 (AF110387) hu
 Italy 2013 (HG325850) hu 
 Italy 2011 (HG325846) hu
 Germany 2006 (FJ705359) wb
 Germany 2013 (KC618403) hu
 Italy 2009 (GQ328905) sw
 Italy 2010 (HG325847) hu
 Italy 2007 (HG325849) hu
 Italy 2005 (HG325851) hu
 Italy 2009 (HG325853) hu
 India 2007 (JF443726) hu
 India 2011 (KJ879476) hu
 Bangladesh 2010 (AB720034) hu
 Bangladesh 2010 (AB720035) hu
 Italy 2009 (FR751532) hu
 Italy 2010 (FR751533) hu
 Italy 2009 (FR751534) hu
 Italy 2009 (FR751535) hu
 Italy 2010 (HG325848) hu
 Italy 2008 (FR751536) hu
 Italy 2006 (HG325852) hu
 Mexico 1992 (M74506) hu
99
79
65
71
61
81
61
67
71
91
99
83
0.02
G3
G1
G2
Hu: human; sw: swine; wb: wild boar.
Sequences of hepatitis E virus isolated from blood donors 771 and 784 in Italy in 2014 are shown in bold. The numbers at the nodes indicate 
bootstrap values ≥ 60%. Sequences are denoted by country, year of isolation (or publication if not available), GenBank accession number in 
parenthesis, and source.
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Figure 2
Maximum likelihood phylogenetic tree based on the Tamura-Nei model for ORF2 nucleotide sequences of selected hepatitis 
E virus strains
 Spain 2009 (EU723513) sw
 Spain 2009 (EU723515) sw
 Spain 2009 (EU723516) sw
 Spain 2000 (AF195062) hu
 Spain 2008 (FJ464744) hu
 Spain 2006 (AY323506) sw
 France 2009 (EU495148) hu 
 Netherlands 2001 (AF336296) sw
 Netherlands 2002 (AY032757) sw 
 Netherlands 2002 (AY032758) sw
 Spain 2000 (AF195061) hu 
 Netherlands 2001 (AF336295) sw
 Italy 2006 (HM446627) hu 
 Netherlands 2002 (AY032759)  sw 
 France 2009 (GQ398024) sw 
 Netherlands 2001 (AF336294) sw
 France 2006 (EF053274) hu
 France 2007 (EU543566) hu 
 Germany 2005 (FJ956757) hu 
 Netherlands 2002 (AF332620) sw
  Netherlands 2001 (AF336292) sw
 Italy 2008 (HM769972) sw 
  Italy 2008 (HM769977) sw
  Italy 2008 (HM769974) sw
 Sweden 2008 (EU360977) sw
 Spain 2009 (EU723512) sw 
 Italy 2003 (HM446629) hu
 Italy 2009 (HM446631) hu
 UK 2005 (AJ879569) hu
 UK 2004 (AF503511) sw
 Italy 2007 (HM446628) hu
 UK 2002 (AF503512) sw 
 UK 2004 (AY362357) hu
 Netherlands 2001 (AF336291) sw
 Netherlands 2001 (AF336299) sw
 Italy 2005 (HM446630) hu 
 Germany 2007 (FJ998008) wb
  Germany 2007 (FJ998012) wb
 Netherlands 2001 (AF336298) sw
 Netherlands 2001 (AF336297) sw
 Netherlands 2002 (AY032756) sw
 Italy 2014 Donor-771-ISS (LN681545)
 Italy 2010 (JN861805) sw
 Italy 2010 (GU556929) sw
 France 2009 (KJ742841) hu 
 Germany 2006 (FJ705359) wb
 Japan 2003 (AB097811) sw
100
98
100
52
78
90
100
60
68
100
100
84
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98
100
82
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56
0.2
3f   
3e   
3a   
3h   
3i   
3c   
4   
Hu: human; sw: swine; wb: wild boar.
Sequence of hepatitis E virus isolated from blood donor 771 in Italy in 2014 is shown in bold. The numbers at the nodes indicate bootstrap 
values ≥ 60%. Sequences are denoted by country, year of isolation (or publication if not available), GenBank accession number in 
parenthesis, and source.
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Table 1
Prevalence of anti-hepatitis E virus IgG antibodies and univariate and multivariate analysis of factors potentially associated 
with infection in blood donors, central Italy, 2014 (n = 313)
Characteristics
Tested HEV IgG+ Univariate analysis Multivariate analysis
N n (%) PR 95% CI p value APRR 95% CI p value
Sex 
Female 61 24 (39) 1.00 Ref Ref Ref Ref Ref
Malea 252 129 (51) 1.30 0.84–2.01 0.24 0.87 0.56–1.35 0.52
Age group (years) 
18–34 54 19 (35) 1.00 Ref Ref Ref Ref Ref
35–44 82 37 (45) 1.28 0.74–2.23
0.19 1.35 0.77–2.35 0.29 45–54 102 51 (50) 1.42 0.84–2.41
≥ 55a 75 46 (61) 1.74 1.02–2.97
Environment 
Birth in rural areaa 107 61 (57) 1.28 0.92–1.76 0.14 1.17 0.84–1.64 0.39
Living in rural area 164 84 (51) 1.10 0.80–1.51 0.56 NI NI NI
Educational level 
Secondary school 93 48 (52) 1.00 Ref Ref NI NI NI
High school 166 77 (46) 0.90 0.63–1.29
0.80 NI NI NI
Master’s degree 54 28 (52) 1.00 0.63–1.60
Professional exposure 
Work with animals 28 17 (61) 1.27 0.77–2.11 0.35 NI NI NI
Contacts with 
Pigs 170 87 (51) 1.10 0.81–1.53 0.53 NI NI NI
Wild boar 51 29 (57) 1.20 0.80–1.80 0.37 NI NI NI
Other wild animals 37 21 (57) 1.19 0.75–1.88 0.47 NI NI NI
Horses 114 53 (47) 0.92 0.66–1.29 0.65 NI NI NI
Poultry 194 98 (51) 1.10 0.79–1.52 0.60 NI NI NI
Sheep 124 58 (47) 0.93 0.67–1.29 0.67 NI NI NI
Cattle 113 62 (55) 1.20 0.87–1.67 0.26 NI NI NI
Other animals 80 38 (48) 0.96 0.67–1.39 0.84 NI NI NI
Dogsa 253 116 (46) 0.74 0.51–1.08 0.12 0.73 0.50–1.07 0.11
Cats 205 100 (49) 1.00 0.71–1.39 0.97 NI NI NI
Hobbies 
Hunting 32 20 (63) 1.32 0.83–2.11 0.25 NI NI NI
Gardening 207 105 (51) 1.12 0.80–1.58 0.51 NI NI NI
Vegetable 
gardeninga 200 106 (53) 1.27 0.90–1.80 0.17 1.23 0.87–1.78 0.24
Eating habits 
Pork 312 152 (49) 0.49 0.07–3.48 0.47 NI NI NI
Game 249 125 (50) 1.15 0.76–1.73 0.51 NI NI NI
Salami 311 151 (49) 0.49 0.12–1.96 0.31 NI NI NI
Raw dried pork sausage 311 152 (49) 0.98 0.14–6.98 0.98 NI NI NI
Raw dried wild boar sausage 225 115 (51) 1.18 0.82–1.71 0.37 NI NI NI
Raw dried pork liver sausagea 253 139 (55) 2.35 1.36–4.08 0.002 2.14 1.23–3.74 0.007
Undercooked/raw meat 80 37 (46) 0.93 0.64–1.34 0.70 NI NI NI
Consumption of vegetables from own kitchen 
garden 244 124 (51) 1.21 0.81–1.81 0.36 NI NI NI
Frequent consumption of vegetables from own 
garden 186 98 (53) 1.22 0.87–1.69 0.24 NI NI NI
Occasional consumption of vegetables from own 
garden 59 27 (46) 0.92 0.61–1.40 0.70 NI NI NI
Travel 
Travel to non-endemic areas 259 127 (49) 1.02 0.66–1.55 0.93 NI NI NI
Travel to endemic areas 118 65 (55) 1.22 0.88–1.68 0.22 NI NI NI
APRR: adjusted prevalence rate ratio; CI: confidence Interval; HEV IgG+: donors testing positive for IgG anti-hepatitis E virus antibodies; NI: not included; PR: 
prevalence ratio.
a Variables initially included in the multivariate binomial regression model because of a p value < 0.20 in the univariate analysis.
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analysis were initially included in the model, while age 
and sex were included independently from the p value. 
A backward selection was then performed and only 
variables with a p value < 0.10 (by the log-likelihood 
ratio test) were retained [30]. Statistical analyses were 
performed using STATA, version 12.
Results
Serological testing and anti-hepatitis E virus 
prevalence
From February to March 2014, 327 blood donors 
attended the blood transfusion unit, of whom 313 (81% 
male; age: 18–68 years, median: 48 years) were suit-
able for donation and agreed to participate to the study 
and to complete the questionnaire. Almost all were 
Italian citizens (99%) and resided in Abruzzo (98%), 
where 84% of donors were also born.
The overall anti-HEV IgG prevalence was 49% (153/313; 
95% CI: 0.43–0.54). As shown in Table 1, preva-
lence was higher, although not significantly, in men 
(p = 0.24). Likewise, no statistically significant differ-
ences were found for educational level (p = 0.80), pro-
fessional exposure (work with animals) (p = 0.35) and 
urban or rural area of birth (p = 0.14) or living (p = 0.56). 
A high anti-HEV IgG prevalence (> 35%) was observed in 
all age groups, without significant differences among 
them (p = 0.19) (Table 1). However, the prevalence 
increased with age, and people older than 55 years 
showed the highest rate.
Two of 313 donors (0.6%; 95% CI: 0.08–2.3) were posi-
tive for anti-HEV IgM, and both were also positive for 
anti-HEV IgG (Table 2).
Factors associated with anti-hepatitis E virus 
IgG positivity
Several potential risk exposures showed in the univari-
ate analysis an association with anti-HEV IgG positiv-
ity with a p value < 0.2 (Table 1): birth in a rural area 
(p = 0.14), contact with dogs (p = 0.12), home vegeta-
ble gardening (p = 0.17) and eating raw dried pig liver 
sausage (p = 0.002). In the multivariate analysis, also 
adjusting for age and sex, only eating raw dried pig liver 
sausage was independently associated with anti-HEV 
IgG positivity (adjusted prevalence rate ratio = 2.14; 
95% CI: 1.23–3.74; p = 0.007).
Detection, quantification and genotyping of 
hepatitis E virus RNA
Three donors (1; 95% CI: 0.20–2.80) showed evidence 
of acute or recent HEV infection. Two donors (0.6%; 
95% CI: 0.08–2.3) were positive for HEV RNA (Table 2). 
One of them (donor 784) had low-level viraemia (100 
IU/mL) and was anti-HEV IgG- and IgM-positive, while 
the other (donor 771) had 10,000 IU/mL of HEV RNA 
and was anti-HEV IgG- and IgM-negative. The third 
one (donor 207), who tested positive for both IgG and 
IgM, was HEV RNA-negative. These three donors were 
completely asymptomatic and their blood donation 
showed normal alanine aminotransferase (ALT) levels. 
All three were tested again for HEV RNA, anti-HEV IgG 
and IgM four to eight months later (Table 2). Donor 207 
was examined five months later and remained HEV 
RNA-negative, while donors 784 and 771 had become 
HEV RNA-negative four and eight months after the 
first blood sampling, respectively. Anti-HEV IgG and 
IgM were positive in all samples obtained during the 
follow-up. Therefore, seroconversion occurred in the 
donor who was negative at the time of donation while 
IgG and IgM persisted in the two others.
The phylogenetic analysis performed using partial 
nucleotide sequences of ORF1 (172 bp) and ORF2 (348 
bp) is shown in Figures 1 and 2, respectively. ORF1 
sequence was amplified from both HEV RNA-positive 
donors, while ORF2 amplification was successful only 
in donor 771, owing to very low-level viraemia in donor 
784. The phylogenetic tree based on ORF1 sequences 
showed that both isolates grouped with HEV3 
sequences (Figure 1). The ORF2 based tree indicated 
that the isolate from donor 771 belonged to subtype 
3c and clustered with very high bootstrap values with 
human and swine 3c sequences from Italy (Figure 2).
Discussion
The observed anti-HEV IgG prevalence is among the 
highest prevalence rates reported in blood donors 
from developed countries [11,12,24]. The demographic 
data and the age distribution of anti-HEV IgG-positive 
donors suggest that HEV infection is hyperendemic 
in the Abruzzo region and virus exposure occurs rela-
tively early in life. However, we observed an increasing 
prevalence with age which is likely to reflect a cumula-
tive exposure to HEV over time.
Such a high anti-HEV IgG prevalence was unexpected, 
since all studies performed so far among Italian blood 
donors reported much lower figures (0.7–9.1%) [19,21-
23]. Indeed, differences in anti-HEV IgG prevalence 
seem to be largely due to the different sensitivity and 
specificity of the assays employed [2,11,13,15] and most 
previous studies, by now outdated, used assays less 
sensitive than the assays currently in use. In the pre-
sent study we used the Wantai IgG ELISA, a validated 
assay which in various comparative studies proved to 
be the most sensitive test available for anti-HEV IgG 
detection, also showing high specificity [2,31,32].
Recent studies using this assay for blood donors in 
Europe showed varying IgG seroprevalence: 4.6% in 
Scotland [12], 10% and 16%, respectively, in the north-
west and south-west of the United Kingdom (UK) [15,33], 
13.6% in Upper Austria [17], 20.0% in Catalonia, Spain 
[16], 19.8% in Denmark [18], 26.7% in the Netherlands 
[34], 39.1% in southern France [24] and 52.6% in the 
Midi-Pyrenees region of south-western France [11].
As these latter studies used the same Wantai IgG ELISA 
assay, sensitivity and specificity could not be a vari-
able affecting the results. Therefore such differences 
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are likely to be genuine, representing true geographi-
cal variation in HEV prevalence due to different types 
and levels of zoonotic exposure. In addition to evident 
zoonotic exposure, such as professional contact with 
animals and consumption of contaminated food, other 
risk factors possibly  linked to zoonotic transmission 
(e.g. ingestion of contaminated water or consumption 
of shellfish ) might play a role in acquiring HEV infec-
tion, but their relative importance remains unknown 
[2]. In the present study, professional exposure to ani-
mals was reported by only 9% of blood donors while 
54% and 16% reported contact with pigs and contact 
with wild boar, respectively. This reflects the common 
habit in the studied area to rear pigs for personal con-
sumption and to hunt boars. However, these three risk 
factors were not associated with a higher risk of HEV 
positivity; this seems in contrast with previous stud-
ies [2,33], but the high prevalence we observed, mainly 
related to dietary habits, could have masked the effect 
of other possible risk factors. In our study, anti-HEV 
IgG positivity was independently associated with eat-
ing raw dried pig liver sausage, a food product widely 
diffused in the study region. Therefore, it may play a 
predominant role in HEV transmission, clearly detect-
able even when analysing a small population. Our data 
are also in agreement with a study carried out among 
blood donors from south-western France, where eat-
ing uncooked pork liver sausages and being male were 
independent predictors of anti-HEV prevalence [24]. In 
addition, cases of an HEV outbreak were linked with 
eating raw pig liver sausage in south-eastern France 
[35]. The risk of infection by eating raw pig liver sau-
sages is likely to be higher than other infection modes 
because liver tissue is the main target of HEV replica-
tion and the viral concentration is therefore expected 
to be very high: an individual is likely to be exposed 
to a higher viral dose when eating raw liver compared 
with other raw meat or sausages [35].
We cannot exclude that other risk factors that only 
played a minor role in our studied population may be 
more prominent when increasing the sample size. Other 
studies showed that particular eating habits might 
explain the spread of infection in a region [2,11,24,35-
37]. According to Legrand-Abravanel et al., eating 
game meat was the only independent predictor of HEV 
infection in French transplant recipients [36]. Offal and 
wild boar consumption emerged as unique independ-
ent predictors of HEV infection in a German study [37]. 
Moreover, a recent study in south-western France car-
ried out in a large population, identified offal and eat-
ing uncooked pork liver sausages as risk factors [24].
Several studies have shown that HEV circulates widely 
in Italian pigs. An HEV RNA prevalence of 42–64.6% 
was found in pigs in northern Italy and the viral 
sequences belonged to HEV3 (specified in one study 
as subtypes 3c and 3f) [38,39]. HEV RNA belonging to 
genotype 3 has been detected in both raw and dried 
pig liver sausages sold at a grocery store in Rome [40].
Also the two HEV RNA-positive donors in our study 
harboured HEV3 genotype; one of them, for whom 
subtyping was successful, belonged to subtype 3c 
and clustered together with other human and swine 
strains from Italy [41]. Preparation and consumption 
of pig liver sausages are widespread throughout the 
Abruzzo region. However, consumption of pig liver sau-
sage could not by itself explain the high anti-HEV IgG 
prevalence we saw among blood donors from Abruzzo, 
because pig liver sausage represents a traditional 
and widely consumed food also in other regions such 
as Latium and Molise. Nevertheless, in a seropreva-
lence study performed during 2009 among 101 blood 
donors from Latium (89% male; median age: 42 years, 
range: 20–62 years) we found an overall anti-HEV IgG 
prevalence of 9% with the same assay employed in 
this study (data not shown). This finding suggests that 
other factors in addition to food-borne transmission 
may have contributed to the high prevalence. Specific 
geographical and demographic factors, not reported 
in other studies, may have had a synergistic effect. 
Firstly, the geographical characteristics of the terri-
tory (mostly mountainous, forested and sparsely popu-
lated) favoured the uncontrolled expansion of the wild 
boar population and may have led to contamination of 
Table 2
Serological and virological features in blood donors with acute/recent hepatitis E virus infection, central Italy, 2014 (n = 3)
Donor Age (years)
Baseline sample Follow-up sample
HEV 
RNA
HEV RNA load 
(IU/mL)
HEV IgM 
(OD)a
HEV IgG 
(OD)b
ALT 
(U/L) GT
TI 
(months)
HEV 
RNA
HEV IgM 
(OD)
HEV IgG 
(OD)
771 50 Pos 10,000 Neg (0.000)
Neg 
(0.001) 13 3c 8 Neg
Pos 
(0.370)
Pos 
(2.954)
784 50 Pos 100 Pos (2.466)
Pos 
(0.423) 10 3 4 Neg
Pos 
(0.766)
Pos 
(1.844)
207 46 Neg NA Pos (0.602)
Pos 
(2.785) 16 NA 5 Neg
Pos 
(0.432)
Pos 
(2.764)
ALT: alanine aminotransferase; GT: genotype; HEV: hepatitis E virus; HEV IgG: anti-HEV IgM antibodies; HEV IgM: anti-HEV IgM antibodies; NA: 
not applicable; neg: negative; OD: optical density; pos: positive; TI: time interval.
a Cut-off OD value for IgM anti-HEV: 0.260.
b Cut-off OD value for IgG anti-HEV: 0.161.
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soil and watercourses. Secondly, almost all study par-
ticipants were born and lived in Abruzzo. More than 
half of them lived in rural areas, had a potentially high 
risk of exposure to HEV-contaminated environment and 
had similar dietary habits.
In this study, the proportion of HEV RNA-positive blood 
donors was 0.6% (2/313), to our knowledge one of the 
highest rates reported among qualified blood donors 
worldwide [10,12,13,24,31,42,43]. Interestingly, the 
three donors showing evidence of acute infection were 
asymptomatic and had normal serum ALT levels. The 
different patterns of HEV RNA and anti-HEV IgG and IgM 
observed in each of them suggests they were in three 
different phases of acute infection (ramp-up phase of 
viraemia, early control and full control of infection). 
This picture is corroborated by the follow-up results: 
HEV RNA clearance occurred in all examined samples, 
associated with seroconversion or persistence of IgG 
and IgM antibodies.
These findings have the following implications: Firstly, 
a small but not negligible proportion of the predomi-
nantly male blood donors (nearly 1%) in Abruzzo have 
evidence of acute/recent HEV infection but are com-
pletely asymptomatic and have normal ALT. Secondly, 
anti-HEV IgM is detectable in only a proportion of 
viraemic donors, as reported by others [13,42,43]. 
Thus, infective donations may escape from being iden-
tified unless viraemia is examined, and such asympto-
matic and viraemic donors are potentially able to cause 
transfusion-transmitted hepatitis E in blood recipients. 
Finally, the coexistence of both IgM and HEV RNA is of 
short duration [13]. Overall, neither ALT measurement 
nor anti-HEV IgM testing seems appropriate to prevent 
transfusion-transmitted HEV infection.
Although the presence of HEV RNA in blood donors 
is not a rare event, only a few cases of transfusion-
transmitted hepatitis E have been reported in devel-
oped countries [25-27] and such cases have never been 
reported in Abruzzo or elsewhere in Italy. It is possi-
ble that the vast majority of transfusion-transmitted 
infections remain asymptomatic and unrecognised, or 
that transmission is hampered by low infectious dose 
and/or high anti-HEV titre in blood donation as well as 
immunity of the recipient, especially important in high 
prevalence regions [44].
We were able to trace two recipients who had received 
red blood cell concentrates from the two viraemic 
donors identified by us. These recipients remained 
uninfected, without markers of HEV infection, up to 
seven months after transfusion and were then lost to 
follow-up.
Some important issues need to be addressed before 
considering implementation of HEV nucleic acid test-
ing in blood screening. These include: the duration of 
HEV viraemia, the minimal infectious dose, the possi-
ble protective effect of anti-HEV antibodies in donors 
and recipients (e.g. nearly half of the Abruzzo popula-
tion, including blood recipients, has anti-HEV IgG), the 
true incidence of symptomatic and asymptomatic acute 
infections in the general population, and the frequency 
of chronic HEV infection in blood recipients.
Published data about all these issues are scarce. In 
Italy, notification of acute hepatitis E to the Italian 
surveillance system for acute viral hepatitis (SEIEVA) 
began only in 2007, and from 2007 to 2014, only 145 
cases of acute infection were reported [45]. This low 
annual incidence markedly disagrees with the anti-HEV 
IgG prevalence found in our study and also in previ-
ous Italian studies [19-23,46-48]. However, virtually 
all acute viral hepatitis cases reported to SEIEVA are 
symptomatic (and hospitalised), while most cases of 
HEV3 and HEV4 acute infection are subclinical or com-
pletely asymptomatic [1,2] and thus pass unrecog-
nised. It is also possible that the discrepancy may, at 
least in part, be due to under-reporting to the surveil-
lance system because of low awareness of healthcare 
professionals.
Some limitations of this study need to be discussed. We 
are aware that the sample of blood donors analysed by 
us was small. However, this limited size made a com-
plete virological analysis possible at affordable cost 
(all donors were tested for anti-HEV IgG and IgM and 
HEV RNA) as well as an evaluation of risk factors for 
infection. Our findings cannot be representative of the 
Italian population of blood donors because the study 
was limited to a restricted geographical area. However, 
a similar epidemiological scenario could exist in other 
countries with similar dietary habits and should be the 
object of further studies.
In addition, our study sample enrolled only 19% 
women, lower than the annual percentage (30%) of 
female blood donors in Italy [46]. However, our study 
covered a period of only two months and this short 
period has probably reduced the chance to enrol female 
blood donors who have a longer inter-donation interval 
than men. Several studies have shown that reasons 
for exclusion or long inter-donation intervals are more 
frequent for women, e.g. lower body weight, lower iron 
levels, lower blood pressure, minor transient health 
problems, pregnancy and breastfeeding [49,50].
Conclusion 
Anti-HEV IgG prevalence among the predominantly 
male blood donors from Abruzzo was high and associ-
ated with eating raw dried pig liver sausage. HEV RNA 
was detected in two donors, who harboured HEV3 and 
were completely asymptomatic, without ALT abnor-
malities. More data are required before considering 
implementing HEV nucleic acid testing in blood donors. 
Recommendations for blood donors and immunocom-
promised patients against eating undercooked pork 
meat would help reduce the risk of HEV infection and 
chronic liver disease.
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